Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 06 Feb 2024 for CNS Pharmaceuticals, Inc., €9,256.
Filing timeline
BuySaleJerzy Gumulka
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
67%
Median T+90
+4.9%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -99.2%Entry US$7,320.00 · Close at T+365 US$55.20
- -89.2%Entry US$55,500.00 · Close at T+365 US$5,970.00
- -90.0%Entry US$61,200.00 · Close at T+365 US$6,120.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jerzy Gumulka: trading record in brief
All filings by Jerzy Gumulka on record concern CNS Pharmaceuticals, Inc. We count 3 filings; the first trade dates from 10 April 2023 and the latest from 1 February 2024.
No open-market sale appears; the market trades are 3 purchases worth €18k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2024 alone, the filings show 1 purchase and no sales.
In size, the median ticket on the buying side is €4,883. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 3 purchases show a median change of +4.9%, with the price up in 67% of them. They describe history only and say nothing certain about the share price ahead.
On 6 February 2024 came the latest disclosure, an open-market purchase for €9,256 in CNS Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jerzy Gumulka
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
33,333 shares@ US$0.3051.4% of flowCommon stockSEC:0001683168-24-000708:0
Canonical exit: 1 May 2024 (T+90)
2,500 shares@ US$1.7021.5% of flowCommon StockSEC:0001683168-23-002562:0
Canonical exit: 18 Jul 2023 (T+90)
7,173 shares@ US$0.7427.1% of flowCommon StockSEC:0001683168-23-002424:0
Canonical exit: 9 Jul 2023 (T+90)
3 of 3 declarations
